AI Blood Test Enables Early Alzheimer's Screening: 94% Accuracy at Under $70
Tsinghua University and Xuanwu Hospital jointly release an AI-driven early Alzheimer's screening solution — a 5ml blood draw combined with deep learning predicts disease onset up to 10 years in advance with 94% accuracy.
Overview
The Tsinghua University Center for Brain Science and Brain-Like Intelligence Research, in collaboration with Xuanwu Hospital of Capital Medical University, today released an AI-driven early Alzheimer's screening solution.
The protocol requires only a 5ml blood draw, measuring concentrations of phosphorylated Tau protein and neurofilament light chain protein, combined with Tsinghua's proprietary NeuroDetect deep learning model to predict disease risk up to 10 years before symptoms appear.
Screening Performance
In a clinical validation of 3,000 cases completed at Xuanwu Hospital:
| Metric | Result |
|---|---|
| Sensitivity | 94.2% |
| Specificity | 91.7% |
| Early warning lead time | 8–10 years |
| False positive rate | 3.1% |
| Cost per test | ~$70 |
Significance and Limitations
Alzheimer's disease has long been a medical enigma — by the time obvious symptoms appear, over 60% of neurons have already been lost, making drug treatment minimally effective. Early screening's value lies in buying a critical window for intervention.
Experts caution, however, that high accuracy doesn't equal diagnosis. Results serve only as high-risk alerts; confirmation still requires PET scans or lumbar puncture.
Rollout Plan
The solution is now available at 8 major cities' top-tier hospitals in Beijing, Shanghai, and Guangzhou, among others. The next phase targets inclusion in national health insurance, aiming to reduce test costs to under $30.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.